Evidence map›Paper›PMID 39188152›Full record

ArticleChemphyschem : a European journal of chemical physics and physical chemistry2024

Exploring the Impact of Protein Chain Selection in Binding Energy Calculations with DFT.

Erik Lindahl, Ran Friedman

Abstract read
In one paragraph

Article in Chemphyschem : a European journal of chemical physics and physical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Exploring the Impact of Protein Chain Selection in Binding Energy Calculations with DFT.Chemphyschem : a European journal of chemical physics and physical chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Erik LindahlDepartment of Chemistry and Biomedical Sciences, Linnæus University, Kalmar, SE-391 82, Sweden.
Ran FriedmanDepartment of Chemistry and Biomedical Sciences, Linnæus University, Kalmar, SE-391 82, Sweden.ORCID 0000-0001-8696-3104

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calculation of binding free energies between a protein and a ligand are highly desired for computer-aided drug design. Here we approximate the binding energies of ABL1, an enzyme which is the target for drugs used in the treatment of chronic myeloid leukaemia, with minimal models and density functional theory (DFT). Starting from the crystal structures of protein-drug complexes, we estimated the binding free energies having used all available individual molecules (protein chains) within each structure, not only a single one as commonly used, in order to see if the choice of the protein chain is important in such calculations. Differences were observed between chains in the same file. Energy decomposition analysis (EDA) revealed that the most important factors for binding were exchange, repulsion and electrostatics. The desolvation term varied dramatically between the inhibitors (between 4.2 and 92.3 kcal/mol). All functionals showed similar patterns in the EDA and in discriminating between the ligands. Non-covalent interactions (NCI) analysis was used to further explain the differences between protein chains and functionals. Overall, it is shown that small minimal models of a drug binding site can be useful to infer on the suitability of an initial crystal structure for further analysis such as EDA.

Indexed as

Density Functional TheoryThermodynamicsBinding SitesHumansLigandsModels, MolecularProtein BindingProto-Oncogene Proteins c-ablABL1 protein, humanLigandsProto-Oncogene Proteins c-ablabsolute binding free energyenzyme inhibitorskinaseprotein-ligand interactions

Identifiers

PMID39188152
PMCPMC11648830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.